secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040948
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta Q2 net loss $33.3M ($0.68/share); cash $302.2M; NKX101 shows 67% CR/CRi with Flu/Ara-C
--------------------------------------------------------------------------------

- Cash and investments $302.2M as of June 30, 2023; cash runway into 2025.
- R&D expense $25.1M; G&A $11.7M; non-cash impairment charge $4.1M on right-of-use assets.
- NKX101: 4/6 CR/CRi (67%) in AML patients after Flu/Ara-C lymphodepletion; no dose-limiting toxicities.
- NKX019 updated data from Phase 1 NHL trial presented at EHA and ICML; expansion cohorts enrolling.
- Alyssa Levin appointed CFO and Chief Business Officer effective July 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023040948/0000950170-23-040948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023040948/nktx-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer